[1]吕培,何红彦,曹红涛,等.冬虫夏草制剂对抗结核药物致肝肾损伤的“减毒”作用及其机制[J].西部中医药,2020,33(03):16-20.[doi:10.12174/j.issn.1004-6852.2020.03.05]
　LYU Pei,HE Hongyan,CAO Hongtao,et al.The "Attenuation" Actions and the Mechanism of Dongchong Xiacao Preparation on Liver and Kidney Injury of Antituberculosis Drugs[J].Western Journal of Traditional Chinese Medicine,2020,33(03):16-20.[doi:10.12174/j.issn.1004-6852.2020.03.05]
点击复制

冬虫夏草制剂对抗结核药物致肝肾损伤的“减毒”作用及其机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年03期
页码:
16-20
栏目:
出版日期:
2020-03-15

文章信息/Info

Title:
The "Attenuation" Actions and the Mechanism of Dongchong Xiacao Preparation on Liver and Kidney Injury of Antituberculosis Drugs
文章编号:
1004-6852(2020)03-0016-05
作者:
吕培，何红彦，曹红涛，高江彦，马静
河北省胸科医院，河北 石家庄 050041
Author(s):
LYU Pei, HE Hongyan, CAO Hongtao, GAO Jiangyan, MA Jing
Hebei Provincial Chest Hospital, Shijiazhuang 050041, China
关键词:
肝损伤; 肾损伤; 免疫功能; 氧化应激; 抗结核药物; 冬虫夏草制剂
Keywords:
liver injury;  kidney injury;  immunologic function;  oxidative stress;  antituberculosis drugs;  Dongchong Xiacao preparations
分类号:
R259
DOI:
10.12174/j.issn.1004-6852.2020.03.05
摘要:
目的：探讨冬虫夏草制剂对抗结核药物致肝肾损伤的“减毒”作用及其机制。方法：将抗结核药物致肝肾损伤患者76例随机分为对照组与观察组各38例，对照组采用2HRZE/4HR方案治疗，观察组在此基础上口服冬虫夏草制剂，每次1.0 g，每日3次，治疗6个月后比较两组患者肝肾功能损伤发生率、外周血CD3+、CD4+、CD8+、CD4+/CD8+及超氧化物歧化酶(Superoxide dismutase，SOD)、丙二醛(malondialdehyde，MDA)、还原型谷胱甘肽(reduced glutathione hormone，GSH)含量，并记录不良反应发生情况。结果：对照组肝功能损伤率为42.1%(16/38)、肾功能损伤率为34.2%(13/38)，高于观察组的15.8%(16/38)、10.5%(4/38)，差异有统计学意义(P＜0.05)。治疗后对照组和观察组外周血CD3+分别为(69.86±4.25)%、(73.06±4.35)%，CD4+分别为(40.35±4.26)%、(43.57±4.68)%，CD4+/CD8+分别为(2.04±0.25)、(2.27±0.26)，SOD分别为(92.35±19.68)U/mL、(108.52±17.24)U/mL，MDA分别为(4.67±1.58)noml/L、(3.36±1.24)noml/L，GSH分别为(6.24±1.25)μmol/L、(7.45±1.34)μmol/L，上述指标两组比较差异有统计学意义(P＜0.05)。结论：冬虫夏草制剂辅助治疗对抗结核药物所致肝肾损伤的“减毒”作用可能与提高患者免疫功能，抗氧化作用相关，且患者耐受性好。
Abstract:
Objective: To investigate the "attenuation" effects and its mechanism of Dongchong Xiacao (cordyceps) preparations on liver and kidney injury of antituberculosis drugs. Methods: All 76 patients were randonly allocated to the control group and the observation group, 38 cases each group, the control group adopted 2HRZE/4HR scheme, and the observation group took Dongchong Xiacao preparations orally, 1.0 g each time, three times each day, to compare the incidence of liver and kidney injury, the contents of GSH, MDA, SOD, CD3+, CD4+, CD8+, CD4+/CD8+ in peripheral blood six months after treating, and record the incidence of adverse reactions. Results: Liver injury rate and kidney injury rate of the control group were 42.1%(16/38) and 34.2%(13/38), higher than 15.8%(16/38) and 10.5%(4/38) of the observation group, and the difference had statistical meaning (P＜0.05). After treating, the contents of CD3+ in peripheral blood of the control group and the observation group were(69.86±4.25)% and (73.06±4.35)%, the contents of CD4+ (40.35±4.26)% and (43.57±4.68)%, CD4+/CD8+ (2.04±0.25) and (2.27±0.26), SOD (92.35±19.68)U/mL and (108.52±17.24)U/mL, MDA (4.67±1.58)noml/L and (3.36±1.24)noml/L, GSH (6.24±1.25)μmol/L and(7.45±1.34)μmol/L, and the difference had statistical meaning between both groups in the comparisons of the indexes above (P＜0.05). Conclusion: Dongchong Xiacao preparations as adjunctive therapy against liver and kidney injury of antituberculosis drugs might be related to raising immunologic function and the effects of oxidative stress, and the patients show good tolerance.

相似文献/References:

[1]黄清杰,李茂星,刘 雄△.中医治疗药物性肝损伤研究进展[J].西部中医药,2012,25(07):124.
　HUANG Qing-jie,LI Mao-xing,LIU Xiong.Progress of Study on Treatment of Drug-induced Liver Injury with TCM[J].Western Journal of Traditional Chinese Medicine,2012,25(03):124.
[2]孟宪华,陈德道,张樱山,等.藏药“桑蒂”抗肝损伤作用机制研究[J].西部中医药,2014,27(01):135.
　MENG Xianhua,CHEN Dedao,ZHANG Yingshan,et al.Study on the Mechanism of Tibetan Medicine "SangDi" Fighting against Liver Damage[J].Western Journal of Traditional Chinese Medicine,2014,27(03):135.
[3]颜春鲁,李盛华△,刘永琦,等.敦煌医方小补肾汤对镉染毒大鼠骨和肾功能的影响[J].西部中医药,2017,30(01):11.
　YAN Chunlu,LI Shenghua,et al.The Influence of Dunhuang Prescription Xiao BuShen Tang on Bone and Renal Functions of the Rats Exposed to Cadmium[J].Western Journal of Traditional Chinese Medicine,2017,30(03):11.
[4]李艳,刘丽丽,杨小军,等.慢性乙型肝炎肝郁脾虚证患者中医证候及实验室指标特征观察[J].西部中医药,2022,35(03):72.[doi:10.12174/j.issn.2096-9600.2022.03.17]
　LI Yan,LIU Lili,YANG Xiaojun,et al.Observation on the Characteristics of TCM Syndromes and Lab Indicators of Patients with Chronic Hepatitis B of Liver Depression and Spleen Deficiency Pattern[J].Western Journal of Traditional Chinese Medicine,2022,35(03):72.[doi:10.12174/j.issn.2096-9600.2022.03.17]
[5]吕超,石清兰,覃倩,等.藏、维两族常用保肝药物研究进展[J].西部中医药,2021,34(07):153.[doi:10.12174/j.issn.2096-9600.2021.07.39]
　LYU Chao,SHI Qinglan,QIN Qian,et al.Advances in Research on Common Liver Protective Drugs Used in Tibetan and Uygur[J].Western Journal of Traditional Chinese Medicine,2021,34(03):153.[doi:10.12174/j.issn.2096-9600.2021.07.39]
[6]乔冬雪,高新,王孟孟,等.急性肾损伤生物标志物在急性肾损伤中的应用及中医药治疗进展[J].西部中医药,2024,37(04):101.[doi:10.12174/j.issn.2096-9600.2024.04.20]
　QIAO Dongxue,GAO Xin,WANG Mengmeng,et al.Application of Acute Kidney Injury Biomarkers in Acute Kidney Injury and Progress of Chinese Medicine Treatment[J].Western Journal of Traditional Chinese Medicine,2024,37(03):101.[doi:10.12174/j.issn.2096-9600.2024.04.20]

备注/Memo

备注/Memo:
收稿日期：2019-09-27*基金项目：河北省2018年度医学科学研究重点课题计划项目(20180682)。作者简介：吕培(1983—)，女，硕士学位，主治医师。研究方向：肝肾损伤的中医药防治。
更新日期/Last Update: 2020-03-15